Morphological changes induced by prostaglandin E in cultured rat osteoblasts.
Prostaglandin E (PGE)-induced morphological changes of osteoblasts and its possible mechanisms were investigated in cultured calvaria and isolated osteoblasts from long bone fragments of neonatal rats. The control osteoblasts, either on the calvaria or isolated from the long bone fragments, were flat, polygonal in shape, and arranged in a monolayer under scanning electron microscopy (SEM) or phase contrast microscopy. Treatment with 1 mumol/L of prostaglandin E2 (PGE2, 2 h) caused these bone cells to contract a soma, whereas 10 and 100 mumol/L PGE2 (2 h) caused 18%-30% of the bone cells to elongate and expose the undersurface. Incubation of the cultured osteoblasts with PGE2 at different time periods showed a bell-shaped pattern with the optimal response at 2 h of incubation. A similar reaction can be induced by treatment with prostaglandin E1 (PGE1) or dibutyryl cyclic adenosine monophosphate (DBcAMP) in combination with 3-isobutyl-1-methylxanthine (IBMX). Furthermore, we assessed the percentage of responsive isolated bone cells to investigate interactions with other agents. The morphological changes induced by PGEs were inhibited by H-8, a protein kinase inhibitor. On the other hand, elevated intracellular calcium enhanced the PGE-induced morphological changes. Fluorescence labeling showed that PGEs caused the breakdown of the actin microfilaments, but spared the microtubules and vimentin filaments in the isolated osteoblast-like cells. These results suggest that the morphological changes of osteoblasts induced by PGEs may be related to the intracellular cAMP and calcium levels.
Yang
R S
RS
Department of Orthopaedics, College of Medicine, National Taiwan University, Taipei. yang@na.mc.ntu.edu.tw
Fu
W M
WM
Wang
S M
SM
Lu
K S
KS
Liu
T K
TK
Lin-Shiau
S Y
SY
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D008841:Actin Cytoskeleton / Q000187:drug effects; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D048429:Cell Size / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008855:Microscopy, Electron, Scanning; D010006:Osteoblasts / Q000187:drug effects* / Q000648:ultrastructure; D010120:Oxytocics / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors; D051381:Rats; D017208:Rats, Wistar; D012886:Skull; D014746:Vimentin / Q000378:metabolism
D004791:Enzyme Inhibitors; D007546:Isoquinolines; D010120:Oxytocics; D010726:Phosphodiesterase Inhibitors; D011458:Prostaglandins E; D047428:Protein Kinase Inhibitors; D014746:Vimentin; D003994:Bucladesine; C053177:N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine